Compare Gartner Inc (IT) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gartner Inc vs Sana Biotechnology Inc — how do they compare? Gartner Inc trades at $186.93 (market cap $11.83B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Gartner Inc is far larger — about 10.5× Sana Biotechnology Inc's market cap. Which is the better fit depends on your goals.
| IT | SANA | |
|---|---|---|
Market Cap | $11.83B | $1.13B |
Sector | Technology | Health |
52-Week High | $264.09 | $5.92 |
52-Week Low | $125.68 | $2.68 |
Enterprise Value | $13.57B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gartner (IT) trades at $179.46, down 7.1% over 24 hours, yet maintains strong fundamentals with a P/E of 16.84 and net income margin of 12%. Recent Q2 2026 earnings beat expectations with EPS of $4.37 versus $3.76 estimated. The stock exhibits a bullish technical signal, supported by positive moving averages, though RSI levels indicate potential overbought conditions. Cash flow trends show operational strength despite a net outflow in 2025.
The outlook remains positive due to consistent earnings beats and raised 2026 guidance, but risks include a shareholder investigation and consulting segment weakness. Analyst consensus is mixed with a $172.80 price target, suggesting cautious optimism amid near-term volatility.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
